Shilpa Medicare's Unit-1 Receives Positive USFDA Inspection Outcome with VAI Classification

Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences Ltd, has received an Establishment Inspection Report (EIR) from the U.S. FDA for its Unit-1, which has been classified as "Voluntary Action Indicated" (VAI). The inspection, conducted from March 3-7, 2025, concluded with no critical issues raised, marking a positive outcome for the company's manufacturing facility. The VAI classification indicates that while no major concerns were found, there may still be minor observations that require corrective actions, which Shilpa Medicare is likely to address promptly. This regulatory approval reinforces Shilpa Medicare's position in the global pharmaceutical market, especially in the U.S., which is a significant revenue generator for the company. Receiving an EIR with a VAI classification allows the company to maintain its operational credibility and continue supplying its products in compliance with U.S. regulations. As a result, this achievement is expected to bolster investor confidence and provide a solid foundation for future business growth.